Ascendis Pharma(US:ASND) Prnewswireยท2024-01-07 19:00Core Points - Specialised Therapeutics Asia Pte Ltd (ST) has entered into an exclusive distribution agreement with Ascendis Pharma A/S for three endocrinology therapies, expanding its portfolio in the region [1][2] - The agreement covers key markets including Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam [1][2] - Two of the therapies, SKYTROFA and YORVIPATH, are already approved internationally, while the third, TransCon CNP, is in development following successful Phase 2 trial results [1][2][3] Product Details - SKYTROFA (lonapegsomatropin) is a once-weekly injectable human growth hormone treatment approved in the US and EU for pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone [2][8] - YORVIPATH (palopegteriparatide) is a first-in-class parathyroid hormone replacement therapy approved in the EU for adults with chronic hypoparathyroidism, addressing a significant unmet medical need [2][3][12] - TransCon CNP (navepegritide) is an investigational therapy for achondroplasia, showing promising results in Phase 2 trials for improving growth velocity in children [1][2][14] Strategic Importance - The partnership marks a significant milestone for ST, indicating its expansion into endocrinology and pediatric medicine [3][4] - ST's CEO emphasized the importance of this agreement in launching critical endocrinology products in the targeted regions [3][4] - Ascendis Pharma's selection of ST as a partner is based on ST's strong track record in commercializing specialist medicines across multiple regions [4][5] Market Context - The agreement aligns with ST's mission to provide specialty therapies where there is an unmet need, enhancing its therapeutic pipeline [6][4] - ST has established itself as the largest independent specialty pharmaceutical company in the region, navigating complex regulatory and commercialization environments [6]